Shares of Clearside Biomedical Inc. (NASDAQ:CLSD) fell 62.8 percent to $2.07 Monday on news that combining its suspension of triamcinolone acetonide (TA) with Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept) failed to help people with retinal vein occlusions (RVO) see any better than treatment with Eylea alone. The Alpharetta, Ga.-based company is discontinuing the RVO program to focus on an application of the same suprachoroidally administered drug as a monotherapy for treating uveitis-associated macular edema. Plans to submit a new drug application in that indication by year-end remain on track, said CEO and President Daniel White.